These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Tamoxifen improves muscle structure and function of Bin1- and Dnm2-related centronuclear myopathies. Gineste C; Simon A; Braun M; Reiss D; Laporte J Brain; 2023 Jul; 146(7):3029-3048. PubMed ID: 36562127 [TBL] [Abstract][Full Text] [Related]
10. Dominant Centronuclear Myopathy with Early Childhood Onset due to a Novel Mutation in BIN1. Kouwenberg C; Bohm J; Erasmus C; van Balken I; Vos S; Kusters B; Kamsteeg EJ; Biancalana V; Koch C; Dondaine N; Laporte J; Voermans N J Neuromuscul Dis; 2017; 4(4):349-355. PubMed ID: 29103045 [TBL] [Abstract][Full Text] [Related]
11. Dynamin-2 mutations associated with centronuclear myopathy are hypermorphic and lead to T-tubule fragmentation. Chin YH; Lee A; Kan HW; Laiman J; Chuang MC; Hsieh ST; Liu YW Hum Mol Genet; 2015 Oct; 24(19):5542-54. PubMed ID: 26199319 [TBL] [Abstract][Full Text] [Related]
12. Mutations in BIN1 associated with centronuclear myopathy disrupt membrane remodeling by affecting protein density and oligomerization. Wu T; Shi Z; Baumgart T PLoS One; 2014; 9(4):e93060. PubMed ID: 24755653 [TBL] [Abstract][Full Text] [Related]
13. Centronuclear myopathies: a widening concept. Romero NB Neuromuscul Disord; 2010 Apr; 20(4):223-8. PubMed ID: 20181480 [TBL] [Abstract][Full Text] [Related]
14. Altered splicing of the BIN1 muscle-specific exon in humans and dogs with highly progressive centronuclear myopathy. Böhm J; Vasli N; Maurer M; Cowling BS; Shelton GD; Kress W; Toussaint A; Prokic I; Schara U; Anderson TJ; Weis J; Tiret L; Laporte J PLoS Genet; 2013 Jun; 9(6):e1003430. PubMed ID: 23754947 [TBL] [Abstract][Full Text] [Related]